title: Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis.
authors.affiliation: The Kennedy Institute of Rheumatology and Imperial College School of Medicine, London.
authors.forename: R N
authors.initials: RN
authors.lastname: Maini
authors.forename: P C
authors.initials: PC
authors.lastname: Taylor
authors.forename: E
authors.initials: E
authors.lastname: Paleolog
authors.forename: P
authors.initials: P
authors.lastname: Charles
authors.forename: S
authors.initials: S
authors.lastname: Ballara
authors.forename: F M
authors.initials: FM
authors.lastname: Brennan
authors.forename: M
authors.initials: M
authors.lastname: Feldmann
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000503:physiopathology* / Q000628:therapy*; D016207:Cytokines / Q000096:biosynthesis; D006801:Humans; D000069285:Infliximab; D009389:Neovascularization, Pathologic / Q000503:physiopathology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology* / Q000502:physiology
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D016207:Cytokines; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab